Glaukos Corp. (GKOS)

63.77
0.75 1.20
NYSE : Health Technology
Prev Close 63.02
Open 62.69
Day Low/High 62.49 / 63.94
52 Wk Low/High 50.60 / 84.65
Volume 192.25K
Avg Volume 526.40K
Exchange NYSE
Shares Outstanding 36.83M
Market Cap 2.27B
EPS -0.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Glaukos' IStent Inject® Delivers Greater IOP Reduction Vs. IStent® According To Newly Published Case Series

Glaukos' IStent Inject® Delivers Greater IOP Reduction Vs. IStent® According To Newly Published Case Series

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that an independent, international case series...

Multiple Presentations To Showcase Glaukos Products At 2019 European Society Of Cataract And Refractive Surgeons Congress

Multiple Presentations To Showcase Glaukos Products At 2019 European Society Of Cataract And Refractive Surgeons Congress

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its products will be included in various...

Glaukos Announces Participation In Wells Fargo Healthcare Conference

Glaukos Announces Participation In Wells Fargo Healthcare Conference

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate...

GKOS Crosses Below Key Price/Book Valuation Level

GKOS Crosses Below Key Price/Book Valuation Level

In trading on Friday, shares of Glaukos Corp crossed below their last reported book value — defined as common shareholder equity per share — of $59.00, changing hands as low as $58.25 per share. Glaukos Corp shares are currently trading off about 4.2% on the day.

ALERT: Rowley Law PLLC Is Investigating Proposed Acquisition Of Avedro, Inc.

ALERT: Rowley Law PLLC Is Investigating Proposed Acquisition Of Avedro, Inc.

NEW YORK, Aug. 8, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Avedro, Inc.

Glaukos Corporation Announces Second Quarter 2019 Financial Results

Glaukos Corporation Announces Second Quarter 2019 Financial Results

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended...

Glaukos And Avedro Announce Definitive Acquisition Agreement

Glaukos And Avedro Announce Definitive Acquisition Agreement

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, and Avedro, Inc.

Glaukos Announces Global Licensing Agreement With Intratus, Inc.

Glaukos Announces Global Licensing Agreement With Intratus, Inc.

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it has entered into a licensing agreement...

Glaukos Corporation To Release Second Quarter 2019 Financial Results After Market Close On August 7

Glaukos Corporation To Release Second Quarter 2019 Financial Results After Market Close On August 7

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2019 financial results after...

Glaukos Corporation Completes Acquisition Of DOSE Medical Corporation

Glaukos Corporation Completes Acquisition Of DOSE Medical Corporation

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel ophthalmic surgical devices and sustained pharmaceutical therapies, announced today that it has...

Glaukos Corporation Enters Into Definitive Agreement To Acquire DOSE Medical Corporation

Glaukos Corporation Enters Into Definitive Agreement To Acquire DOSE Medical Corporation

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel ophthalmic surgical devices and sustained pharmaceutical therapies, announced today that it has entered...

International Study Confirms Significant, Sustained IOP And Medication Reduction Following Standalone Implantation Of Glaukos' IStent Inject® In Glaucoma Patients With Substantial Disease Burden

International Study Confirms Significant, Sustained IOP And Medication Reduction Following Standalone Implantation Of Glaukos' IStent Inject® In Glaucoma Patients With Substantial Disease Burden

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of...

Glaukos Announces Participation In William Blair Growth Stock Conference

Glaukos Announces Participation In William Blair Growth Stock Conference

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of...

Glaukos Corporation Announces First Quarter 2019 Financial Results

Glaukos Corporation Announces First Quarter 2019 Financial Results

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of...

Multiple Surgeons To Present Data On Glaukos Technologies At 2019 American Society Of Cataract And Refractive Surgery

Multiple Surgeons To Present Data On Glaukos Technologies At 2019 American Society Of Cataract And Refractive Surgery

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of...

Glaukos Announces Participation In Bank Of America Merrill Lynch 2019 Health Care Conference

Glaukos Announces Participation In Bank Of America Merrill Lynch 2019 Health Care Conference

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of...

Glaukos Corporation To Release First Quarter 2019 Financial Results After Market Close On May 8

Glaukos Corporation To Release First Quarter 2019 Financial Results After Market Close On May 8

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of...

Prospective, Randomized Trial Highlights 5-Year Performance Of 2 Standalone Glaukos IStents® Vs. Topical Prostaglandin In Newly Diagnosed Glaucoma Patients

Prospective, Randomized Trial Highlights 5-Year Performance Of 2 Standalone Glaukos IStents® Vs. Topical Prostaglandin In Newly Diagnosed Glaucoma Patients

Glaukos Corporation (NYSE:GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma,...

Pivotal Trial Results For Glaukos' IStent Inject® Published In Leading Ophthalmic Journal

Pivotal Trial Results For Glaukos' IStent Inject® Published In Leading Ophthalmic Journal

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of...

Glaukos Technologies Featured In Numerous Presentations At 2019 American Glaucoma Society Meeting

Glaukos Technologies Featured In Numerous Presentations At 2019 American Glaucoma Society Meeting

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of...

International Glaucoma Study Confirms Long-term Efficacy And Safety Profile Of Glaukos IStent® Implantation In Combination With Cataract Surgery

International Glaucoma Study Confirms Long-term Efficacy And Safety Profile Of Glaukos IStent® Implantation In Combination With Cataract Surgery

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of...

Glaukos Corporation Announces Fourth Quarter And Full Year 2018 Financial Results

Glaukos Corporation Announces Fourth Quarter And Full Year 2018 Financial Results

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of...

GKOS Crosses Above Average Analyst Target

GKOS Crosses Above Average Analyst Target

In recent trading, shares of Glaukos Corp have crossed above the average analyst 12-month target price of $68.75, changing hands for $69.40/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Glaukos Corporation To Release Fourth Quarter And Full Year 2018 Financial Results After Market Close On February 27

Glaukos Corporation To Release Fourth Quarter And Full Year 2018 Financial Results After Market Close On February 27

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of...

Glaukos Announces Participation In J.P. Morgan Healthcare Conference

Glaukos Announces Participation In J.P. Morgan Healthcare Conference

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of...

Glaukos IStent Inject® Implantation With Concomitant Cataract Surgery Provides Sustained Reduction In IOP And Medication Burden, According To New Study

Glaukos IStent Inject® Implantation With Concomitant Cataract Surgery Provides Sustained Reduction In IOP And Medication Burden, According To New Study

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of...

Glaukos Announces Participation In Piper Jaffray Healthcare Conference

Glaukos Announces Participation In Piper Jaffray Healthcare Conference

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of...

TheStreet Quant Rating: C- (Hold)